AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AROA BIOSURGERY LTD

0.585

-0.005-0.85%

Volume:106.29K

Turnover:62.31K

Market Cap:201.84M

PE:-57.08

High:0.595

Open:0.570

Low:0.570

Close:0.590

Loading ...

Overview Company News Filings

Discover 3 ASX Penny Stocks With Market Caps Over A$100M

Simply Wall St.

Appendix 4G and Corporate Governance Statement-ARX.AX

Aroa Biosurgery FY Adjusted Pretax Profit Nzd 117 Thousand

THOMSON REUTERS

Annual Report to Shareholders-ARX.AX

Notice of AGM Date and Director Nomination Closing Date-ARX.AX

Change of Director's Interest Notice - JD-ARX.AX

These small cap ASX shares could rise 50% to 65%

Aroa Biosurgery's Growth Momentum Looks Set to Continue -- Market Talk

Aroa Biosurgery's Loss Narrows in Fiscal Year 2025 as Revenue Rises

MT Newswires Live

Which small cap ASX share is jumping 10% on strong results

BUZZ-ASX-listed Aroa Biosurgery rises to 3-month high on upbeat FY results, outlook

BRIEF-Aroa Biosurgery Posts FY Product Revenue NZD 84 Million

Aroa Biosurgery Sees FY Normalised Ebitda of Nz$5-8 Mln

THOMSON REUTERS

Aroa Biosurgery FY Product Revenue Nzd 84.7 Million

THOMSON REUTERS

Aroa Biosurgery FY Gross Profit Nzd 72.6 Million

THOMSON REUTERS

AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.

3 ASX Penny Stocks With Market Caps Under A$400M

Simply Wall St.

BRIEF-Aroa Biosurgery Expects Net Impact Of New Us Import Tariffs To Be Substantially Lower Than 10%

Aroa Biosurgery - Aroa Expects Net Impact of New US Import Tariffs to Be Substantially Lower Than 10%

THOMSON REUTERS

Aroa Biosurgery Limited's (ASX:ARX) Profit Outlook

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARX.AU\",,,,,undefined,":{"symbol":"ARX.AU","market":"AU","secType":"STK","nameCN":"AROA BIOSURGERY LTD","latestPrice":0.585,"timestamp":1751868720000,"preClose":0.59,"halted":0,"volume":106286,"delay":0,"nameEN":"AROA BIOSURGERY LTD","floatShares":259765068,"shares":345033235,"eps":-0.010248646301790409,"marketStatus":"Not Yet Opened","change":-0.005,"latestTime":"07-07 16:12:00 AEST","open":0.57,"high":0.595,"low":0.57,"amount":62308,"amplitude":0.042373,"askPrice":0.595,"askSize":20402,"bidPrice":0.585,"bidSize":1985,"shortable":3,"etf":0,"ttmEps":-0.010248646301790409,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1751932800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.59,"openAndCloseTimeList":[[1751846400000,1751868000000]],"volumeRatio":0.7237873438807362,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARX.AU\",,,,,undefined,":{"symbol":"ARX.AU","floatShares":259765068,"roa":"-1.66%","roe":"-4.06%","lyrEps":-0.010207,"volumeRatio":0.7237873438807362,"shares":345033235,"dividePrice":0,"high":0.595,"amplitude":0.042373,"preClose":0.59,"low":0.57,"week52Low":0.35,"pbRate":"2.35","psRate":"2.58","week52High":0.815,"institutionHeld":0,"latestPrice":0.585,"committee":-0.822665,"eps":-0.010248646301790409,"divideRate":0,"volume":106286,"delay":0,"ttmEps":-0.010248646301790409,"open":0.57,"prevYearClose":0.77,"prevWeekClose":0.59,"prevMonthClose":0.58,"prevQuarterClose":0.58,"fiveDayClose":0.58,"twentyDayClose":0.52,"sixtyDayClose":0.385},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548012460","title":"Discover 3 ASX Penny Stocks With Market Caps Over A$100M","url":"https://stock-news.laohu8.com/highlight/detail?id=2548012460","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548012460?lang=en_us&edition=fundamental","pubTime":"2025-06-30 11:04","pubTimestamp":1751252696,"startTime":"0","endTime":"0","summary":"As the Australian stock market navigates the close of a turbulent financial year, it reflects a global trend of cautious optimism bolstered by strong performances in U.S. markets. Penny stocks, though often considered a relic from past market eras, continue to offer intriguing investment opportunities by highlighting smaller or newer companies that may be overlooked. By focusing on those with robust financials and potential for growth, investors can uncover promising prospects among these lesser-known equities.Overview: Aroa Biosurgery Limited is a company that develops, manufactures, and sells medical devices for wound and soft tissue repair using ECM technology, with a market cap of A$193.22 million.Overview: COSOL Limited, with a market cap of A$115.56 million, provides information technology services across the Asia Pacific, North America, Europe, the Middle East, Africa, and other international markets.Operations: The company's revenue is derived from its Asia Pacific segment, con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discover-3-asx-penny-stocks-030456163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU1861217088.USD","COS.AU","IGL.AU","LU1791807156.HKD","BK7048","LU1668664300.SGD","MLX.AU","XAO.AU","EZZ.AU","LU1861220207.SGD","LU2360107671.USD","BK7062","AAL.AU","BK7016","CLX.AU","GTN.AU","BK7058","BK7077","BK4166","BK4585","BK4588","LU0106831901.USD","XKO.AU","LAU.AU","BIS.AU","SXE.AU","BK7055","BK7125","NGI.AU","BK7163","BK7129","BK7507","BK7045","BK7067","XJO.AU","BK7095","ARX.AU","DFS"],"gpt_icon":0},{"id":"2546766007","title":"Appendix 4G and Corporate Governance Statement-ARX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546766007","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546766007?lang=en_us&edition=fundamental","pubTime":"2025-06-27 09:29","pubTimestamp":1750987794,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250627:nASX169QDl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nASX7tSrNp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ISLV","BK7067","ARX.AU"],"gpt_icon":0},{"id":"2546765693","title":"Aroa Biosurgery FY Adjusted Pretax Profit Nzd 117 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2546765693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546765693?lang=en_us&edition=fundamental","pubTime":"2025-06-27 09:29","pubTimestamp":1750987793,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nPLX9B2390:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2546698857","title":"Annual Report to Shareholders-ARX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546698857","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546698857?lang=en_us&edition=fundamental","pubTime":"2025-06-27 09:29","pubTimestamp":1750987784,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250627:nASXdzkDc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nASXc0PwGN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2546260644","title":"Notice of AGM Date and Director Nomination Closing Date-ARX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546260644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546260644?lang=en_us&edition=fundamental","pubTime":"2025-06-25 13:53","pubTimestamp":1750830812,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250625:nASX5Fq4mk","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nASX1BfqZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2542791393","title":"Change of Director's Interest Notice - JD-ARX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2542791393","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542791393?lang=en_us&edition=fundamental","pubTime":"2025-06-11 09:50","pubTimestamp":1749606642,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250611:nASX98nMfF","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nASX5qfNh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2539942271","title":"These small cap ASX shares could rise 50% to 65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2539942271","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539942271?lang=en_us&edition=fundamental","pubTime":"2025-05-31 00:38","pubTimestamp":1748623080,"startTime":"0","endTime":"0","summary":"If you have a high tolerance for risk and are on the hunt for big returns, then look no further. That's because analysts at Bell Potter have named the two small cap ASX shares listed below as buys wit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/31/these-small-cap-asx-shares-could-rise-50-to-65/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IDX.AU","ARX.AU","BK7067","BK7124"],"gpt_icon":0},{"id":"2539521848","title":"Aroa Biosurgery's Growth Momentum Looks Set to Continue -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2539521848","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539521848?lang=en_us&edition=fundamental","pubTime":"2025-05-30 09:39","pubTimestamp":1748569140,"startTime":"0","endTime":"0","summary":"0139 GMT - Aroa Biosurgery's conservative revenue guidance implies that the wound-treatment company's elevated growth momentum should continue, according to Wilsons analysts. They write in a note that the guidance is seen as achievable by the market, adding that they anticipate a potentially significant increase in productivity from its Myriad product sales reps in fiscal 2026. They reckon that the stock should trade in line with wound-care peers at three times 2026 revenue. Wilsons lifts its target price 9.3% to A$0.82 and stays overweight on the stock, which is flat at A$0.53. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2539381982","title":"Aroa Biosurgery's Loss Narrows in Fiscal Year 2025 as Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2539381982","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539381982?lang=en_us&edition=fundamental","pubTime":"2025-05-29 13:38","pubTimestamp":1748497138,"startTime":"0","endTime":"0","summary":"Aroa Biosurgery  reported Thursday that its fiscal year 2025 loss narrowed to NZ$0.0111 per diluted share from a loss of NZ$0.0309 per diluted share a year earlier.Analysts polled by Visible Alpha were expecting a loss per diluted share of NZ$0.6.Revenue for the year ended March 31 was NZ$84.7 million, up 23% from NZ$69.1 million in the same period last year. Analysts surveyed by Visible Alpha expected NZ$81.1 million.For fiscal year 2026, the company expects revenue in the range of N$92 million to NZ$100 million. Analysts polled by Visible Alpha expect earnings of NZ$1.1 per diluted share on revenue of NZ$102.2 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARX.AU"],"gpt_icon":0},{"id":"2539238237","title":"Which small cap ASX share is jumping 10% on strong results","url":"https://stock-news.laohu8.com/highlight/detail?id=2539238237","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539238237?lang=en_us&edition=fundamental","pubTime":"2025-05-29 13:30","pubTimestamp":1748496643,"startTime":"0","endTime":"0","summary":"The Australian share market is on form on Thursday. In afternoon trade, the benchmark ASX 200 index is up 0.25%. While this is positive, it pales in comparison to what one small cap ASX share is recording today. Which small cap ASX share?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/29/which-small-cap-asx-share-is-jumping-10-on-strong-results/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2539528398","title":"BUZZ-ASX-listed Aroa Biosurgery rises to 3-month high on upbeat FY results, outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2539528398","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539528398?lang=en_us&edition=fundamental","pubTime":"2025-05-29 08:52","pubTimestamp":1748479942,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Aroa Biosurgery rises to 3-month high on upbeat FY results, outlook** Shares of Aroa Biosurgery ARX.AX rise 14.9% to A$0.540, their highest levels since February 27** Stock set for its strongest session since October 22, 2024 - if current trends hold** The soft-tissue regeneration products maker posts normalised FY EBITDA profit of NZ$4.2 million  compared to an EBITDA loss NZ$3.1 million last year** Co sees FY26 normalised EBITDA of NZ$5 million - NZ$8 million** Stock on track for fifth consecutive session of gains, if current trends hold ** Stock down 29.9% YTD, including current session's moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nL3N3S101Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2539407863","title":"BRIEF-Aroa Biosurgery Posts FY Product Revenue NZD 84 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2539407863","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539407863?lang=en_us&edition=fundamental","pubTime":"2025-05-29 06:44","pubTimestamp":1748472297,"startTime":"0","endTime":"0","summary":"BRIEF-Aroa Biosurgery Posts FY Product Revenue NZD 84 Million May 29  - Aroa Biosurgery Ltd ARX.AX:FY PRODUCT REVENUE NZD 84 MILLION FY ADJUSTED EBITDA NZD 4.2 MILLIONFY PRODUCT GROSS MARGIN 86%FY ADJUSTED EBIT NZD -800 THOUSANDFY GROSS PROFIT NZD 72.6 MILLIONFY ADJUSTED OPERATING EXPENSES NZD 74.5 MILLIONTOTAL REVENUE GUIDANCE OF NZ$92-100 MILLION FOR FY26SEES FY NORMALISED EBITDA OF NZ$5-8 MILLIONFurther company coverage: ARX.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nL5N3S02AB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BRIEF-Aroa Biosurgery Posts FY Product Revenue NZD 84 Million","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX.AU"],"gpt_icon":0},{"id":"2539782402","title":"Aroa Biosurgery Sees FY Normalised Ebitda of Nz$5-8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2539782402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539782402?lang=en_us&edition=fundamental","pubTime":"2025-05-29 06:39","pubTimestamp":1748471996,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nPLXA4E8AC:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2539402269","title":"Aroa Biosurgery FY Product Revenue Nzd 84.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2539402269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539402269?lang=en_us&edition=fundamental","pubTime":"2025-05-29 06:39","pubTimestamp":1748471996,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nPLXA4E8AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2539402250","title":"Aroa Biosurgery FY Gross Profit Nzd 72.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2539402250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539402250?lang=en_us&edition=fundamental","pubTime":"2025-05-29 06:39","pubTimestamp":1748471996,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nPLXA4E8AC:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2532285727","title":"AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.","url":"https://stock-news.laohu8.com/highlight/detail?id=2532285727","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532285727?lang=en_us&edition=fundamental","pubTime":"2025-05-02 10:42","pubTimestamp":1746153720,"startTime":"0","endTime":"0","summary":"AUCKLAND, New Zealand, May 1, 2025 /PRNewswire/ -- Soft tissue regeneration company,Aroa Biosurgery, is pleased to announce a milestone in clinical evidence.There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology.AROA's most recent publication was a large retrospective analysis of real-world evidence  from wound care centers in the US, assessing the efficacy of the company's Endoform NaturalTM product in treating venous leg ulcers , in comparison to a leading reconstituted collagen dressing.VLU's are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful. These types of wounds are difficult for clinicians to treat successfully. For example, only ~40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur[1].This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituted collagen dre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/aroa-hits-evidence-milestone-real-024200301.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aroa-hits-evidence-milestone-real-024200301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2532880063","title":"3 ASX Penny Stocks With Market Caps Under A$400M","url":"https://stock-news.laohu8.com/highlight/detail?id=2532880063","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532880063?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:02","pubTimestamp":1746129720,"startTime":"0","endTime":"0","summary":"The Australian market has shown mixed performance, with the ASX200 closing up 0.24% at 8,145 points, driven by gains in the IT and Real Estate sectors while Energy and Materials faced declines. In such a varied landscape, identifying stocks with robust financials becomes crucial for investors seeking opportunities beyond the major players. Penny stocks, often representing smaller or newer companies, continue to offer potential for growth when they are backed by solid fundamentals.Overview: Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix technology, with a market cap of A$151.76 million.Baby Bunting Group Limited, with a market cap of A$211.15 million, is seeing mixed finan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-penny-stocks-market-200200901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["AX1.AU","ARX.AU","GTN.AU","NGI.AU","NWH.AU","BK7506","BK7129","BK7045","CLX.AU","BK7055","BK7048","BK7021","WAF.AU","BK7128","BK7104","BK7067","BK7058","BIS.AU","IGL.AU","PTM.AU","BK7062","RPL.AU","BBN.AU","EZZ.AU"],"gpt_icon":0},{"id":"2531216347","title":"BRIEF-Aroa Biosurgery Expects Net Impact Of New Us Import Tariffs To Be Substantially Lower Than 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531216347","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531216347?lang=en_us&edition=fundamental","pubTime":"2025-04-29 09:44","pubTimestamp":1745891075,"startTime":"0","endTime":"0","summary":"BRIEF-Aroa Biosurgery Expects Net Impact Of New Us Import Tariffs To Be Substantially Lower Than 10%April 29  - Aroa Biosurgery Ltd ARX.AX:AROA EXPECTS NET IMPACT OF NEW US IMPORT TARIFFS TO BE SUBSTANTIALLY LOWER THAN 10%Further company coverage: ARX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62KA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2531293163","title":"Aroa Biosurgery - Aroa Expects Net Impact of New US Import Tariffs to Be Substantially Lower Than 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531293163","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531293163?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:47","pubTimestamp":1745880447,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R62KA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2529434368","title":"Aroa Biosurgery Limited's (ASX:ARX) Profit Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2529434368","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529434368?lang=en_us&edition=fundamental","pubTime":"2025-04-21 12:11","pubTimestamp":1745208714,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Aroa Biosurgery Limited's  future prospects. Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix  technology in the United States and internationally. The AU$140m market-cap company posted a loss in its most recent financial year of NZ$11m and a latest trailing-twelve-month loss of NZ$7.6m shrinking the gap between loss and breakeven. Many investors are wondering about the rate at which Aroa Biosurgery will turn a profit, with the big question being “when will the company breakeven?”We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.Working backwards from analyst estimates, it turns out that they expect the company to grow 60% year-on-year, on average, which is extremely buoyant. Should the business grow at a slower rate, it will","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aroa-biosurgery-limiteds-asx-arx-041154212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ARX.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-06-30","symbol":"ARX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1751241600000,"name":null,"time":"","dateTimestamp":1751205600000,"actualEps":null},{"date":"2025-05-29","symbol":"ARX.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1748476800000,"name":null,"time":"Pre-Market","dateTimestamp":1748440800000,"actualEps":null},{"date":"2025-04-29","symbol":"ARX.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1745884800000,"name":null,"time":"Pre-Market","dateTimestamp":1745848800000,"actualEps":null},{"date":"2025-01-28","symbol":"ARX.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1738018800000,"name":null,"time":"Pre-Market","dateTimestamp":1737982800000,"actualEps":null},{"date":"2024-10-21","symbol":"ARX.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1729465200000,"name":null,"time":"Pre-Market","dateTimestamp":1729429200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARX.AU\",market:\"AU\",,,undefined,":[]}}